8-K - Sangamo Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Sangamo Therapeutics reported a consolidated net loss of $122.9 million for the full year 2025, with cash and equivalents of $20.9 million as of December 31, 2025, and expects its cash to fund operations into Q3 2026.

Key Takeaways

1Full year 2025 net loss widened to $122.9M from $97.9M in 2024, indicating increased operational expenses.

2Cash and equivalents decreased to $20.9M as of Dec 31, 2025, from $41.9M a year prior, raising liquidity concerns.

3Company initiated rolling BLA submission for Fabry disease gene therapy ST-920 under Accelerated Approval pathway.

4Received Fast Track Designation for neurology candidate ST-503 and activated six clinical sites for its Phase 1/2 study.

5Raised over $130M in funding since start of 2025 through license fees, milestone payments, and equity financing.

6Provided 2026 GAAP operating expense guidance of $120M-$140M, contingent on securing additional funding.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities

Financial Results

9.01

Financial Statements and Exhibits. (d) Exhibits . Exhibit No.: 99.1 | Description: Press Release regarding financial results dated March 30, 2026 Exhibit No.: 1

Exhibits Only

Source Document

Results of Operations

Year Ended December 31, 2025

Metric	Value	Prior Period
Revenue	$39.60	$57.80
Net Income	$-122.90	$-97.90
Diluted EPS	$-0.44	$-0.49
Research and Development Expenses	$112.70	$111.50
General and Administrative Expenses	$34.90	$44.80

Forward Guidance

Full Year 2026

Total Operating Expenses

120140

GAAP

Total Operating Expenses

110120

Non-GAAP

Exhibits (2)

8-K

99.1

EX-99.1